Introduction: B-chronic lymphocytic leukemia is a malignant tumor of mature B lymphocytes. The disease is characterized by progressive accumulation of small lymphocytes of monoclonal origin in the bone marrow, peripheral blood and lymph nodes. Median survival of people suffering from this disease is difficult to determine because the survival is diferent for every individual. Prognostic markers are consistently researched in order to better assess the individual state of the disease and the risk of progression in earlier stages of the disease. Objective: The aim of this study was to compare CD38 values with prognostic markers: LDH, β2-microglobulin, absolute lymphocytes and the percentage of lymphocytes. Then, the examinees were separated into two groups based on the CD38 positivity, and each group was compared with the prognostic markers mentioned above. Methods: The expression of CD38 markers on clonal B-KLL cells was determined by the direct immunofluorescent assay method and measured by flow cytometry. Results: The comparison of CD38 shows poor correlation with β2-microglobulin, while with it does not correlate at all with other parameters. CD38 expression values on clonal cells differ significantly between the CD38 positive and CD38 negative subjects. A significant difference was found between these two groups for LDH and β2-microglobulin parameters. Conclusion: CD38 is an early prognostic biomarker, which proved to be particularly good biomarker in combination with LDH and β2-microglobulin.